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Excess a-synuclein worsens disease in
mice lacking ubiquitin carboxy-terminal
hydrolase L1
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Mutationsina-synuclein(aSN)andubiquitincarboxy-terminalhydrolaseL1(UCH-L1)havebeenlinkedto
familial Parkinson’s disease (PD). Physical and functional interactions between these two proteins have
beendescribed.Whethertheyactadditivelyinvivotoinfluencediseasehasremainedcontroversial.aSNisa
presynaptic protein and the major constituent of Lewy inclusions, histopathological hallmarks of PD.
UCH-L1 regulates ubiquitin stability in the nervous system and its loss results in neurodegeneration in
peripheralandcentralneurons.Here,weusedgeneticstoshowthatUCH-L1-deficiencytogetherwithexcess
aSNworsendisease.Doublemutantmiceshowearlier-onsetmotordeficits,ashorterlifespanandforebrain
astrogliosis but the additive disease-worsening effects of UCH-L1-deficiency and excess aSN are not
accompaniedbymicrogliosis,ubiquitinpathologyorchangesinpathologicalaSNproteinlevelsandspecies.
P
arkinson’s disease (PD) is a progressive neurodegenerative disorder that affects approximately 1% of the
population older than 65 years of age. Disabling clinical manifestations are caused by a selective loss of
dopaminergic (DA) neurons in the substantia nigra pars compacta (SNc) and include tremor, bradykinesia
and stiffness. DA neuronal cell loss is accompanied by an immunopathology in DA and other neurons: eosino-
philicintraneuronalinclusionsreferredtoaseitherLewybodies(LBs)orLewyneurites(LNs).Botharecomposed
mainlyofa-synuclein(aSN)andoftenalsoubiquitin(Ub).LikeinPD,Lewyinclusionsareadefinedpathological
hallmarkof anothera-synucleinopathydisease referred toasdementiawithLewy bodies(DLB;forreviewsee
1,2).
DLBissecondafterthemostcommonneurofibrillary pathologythatcharacterizesAlzheimer’sdisease(AD)and
often both pathologies co-occur in the same individual. In contrast to AD pathology, Lewy pathology is not
restricted to central neurons but also occurs in peripheral neurons and nerves including the gastrointestinal
nervous system and cardiac nerves
3.
Inrecentyears,hopehasrisentobetterunderstandthepathophysiologyofa-synucleinopathies.Theevidence,
that the accumulation of non-physiological levels and forms of the synaptic protein aSN plays a central role in
disease pathogenesis is overwhelming
4: (i) aSN accumulates in LBs
5–7; (ii) specific mutations in aSN causing a
single amino-acid change (A30P, A53T, E46K) as well as duplication or triplication of the wildtype aSN gene
cause rare familial forms of parkinsonism
8–11; (iii) neuronal over-expression of either wildtype or mutant human
aSN in transgenic flies, rodents and non-human primates causes a-synucleinopathy
12–16. Nonetheless, the
molecular mechanisms causing a non-physiological accumulation of aSN and/or aSN-induced neuronal dys-
function and death have remained largely elusive.
The enzyme ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) is primarily expressed in neurons and has
been implicated in neurodegenerative diseases including PD as well as cancer
17,18. UCH-L1 protein is abundant
and widely expressed in the brain (1–2% of total protein). The enzyme has de-ubiquitylating
19,20 as well as
ubiquitylating activity
21, and the protein functions to stabilize mono-ubiquitin
22. UCH-L1 protein is found in
Lewy bodies
23. A missense mutation (I93M) in UCH-L1 (UCH-L1
I93M) was discovered in a German family
affected by autosomal dominant familial PD
24. Other reports linking UCH-L1 variants as risk factors for PD
haveremainedcontroversial
25–27.MicenaturallylackingUCH-L1developgracileaxonal dystrophy(gad),exhibit
an age-dependent sensory ataxic phenotype and motor paresis, manifest a dying-back axonal degeneration in
sensory and motor nerve terminals and display b-synuclein (bSN) and c-synuclein (cSN) pathology but, inter-
estingly, lack aSN pathology
28–30. Evidence from two additional different UCH-L1-deficient mouse mutants
showed that UCH-L1 is required for maintaining the structure and function of central and peripheral
synapses
31,32.Noneofthesemutantsseemstoshowpathologicalchangesindopaminergicneuronsandtheextent
of viral vector-mediated expression and aSN-induced cell loss in DA neurons is exacerbated in UCH-L1
I93M
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wildtype) or gad
mice
33. All these findings seem consistent with a gain-of-toxic func-
tion of the UCH-L1
I93M mutant but little or no function of UCH-
L1
wildtype or its lack in aSN-induced DA damage.
Also in line with this hypothesis are the reports that over-express-
ion of the UCH-L1
I93Mmutant in vitro causes accumulation of aSN
34
and in mice leads to DA neuronal cell loss
35. Nonetheless, other
findings suggest that also UCH-L1
wildtype has a role in aSN-induced
neurotoxicity and aSN protein homeostasis: (i) different forms of
UCH-L1 de-ubiquitinate poly-ubiquitinated aSN
36,37 or act as an
aSN ubiquitin ligase
21; (ii) UCH-L1 levels are reduced and activity
is down by 40-80% because of oxidative damage in idiopathic PD,
DLB and AD brains
38,39; (iii) reducing the membrane-bound from of
UCH-L1 in cell culture models of aSN toxicity reduces aSN levels
andincreases cell viability
40.Here, weused mousegenetics to further
elucidate a potential synergistic effect of UCH-L1-deficiency and
excess aSN in disease.
Results
Excess aSN worsens disease in UCH-L1-deficient mice. To test
whether excess aSN and the lack of UCH-L1 have additive effects
on disease worsening or outcome, we generated via breeding double
transgenic mice over-expressing wildtype mouse aSN
41 (Thy1-
maSN) and lacking UCH-L1 [Deltagen (Uchl1
tm1Dgen; ID: MGI:
3604452)]. We studied UCH-L1-deficiency in the context of an
excess of murine wildtype aSN to avoid confounds that might
arise because of cross-species differences in human and mouse
aSN and/or UCH-L1 function. Double Uchl1
tm1Dgen:Thy1-maSN
transgenic mice (referred to as UCH-L1
2/2/Thy1-maSN hereafter),
and their single mutant UCH-L1
2/2 and Thy1-maSN littermates
were subsequently characterized with respect to weight, muscle
strength (grip strength), motor coordination (rotating beam per-
formance) and a-synucleinopathy related changes at histopa-
thological and biochemical levels. At 2.5 months of age, wildtype
control littermates and Thy1-maSN mice showed no difference in
weight (Figure 1A), grip strength (Figure 1B) or rotating beam
performance (Figure 1C and 1D). In contrast, at this age UCH-
L1
2/2 mice showed already a slight weight-loss (Figure 1A) and
motor deficits on the rotating beam (Figure 1C and 1D), a
phenotype similar to that described for UCH-L1 deficient gad
mice
42. Muscle weakness in UCH-L1
2/2 mice was not yet apparent
at the age of 2.5 months (Figure 1B) but very prominent at the age of
4.5months(0.62 N60.14versuslittermatecontrols1.32 N60.14).
Heterozygous UCH-L1 deficient mice did not show these deficits
(data not shown). As compared to UCH-L1
2/2 mice, 2.5 months
old UCH-L1
2/2/Thy1-maSN double mutant mice showed greater
deficits in both muscle strength (Figure 1B) and motor coordi-
nation (Figure 1C and 1D) whereas weight did not differ sig-
nificantly (Figure 1A). At the age of 3.5 months, the general health
state of double mutant mice was such, that the animals had to be
Figure 1 | Weight,musclestrengthandmotorbehaviorinUCH-L1
2/2/Thy1-maSNdoubletransgenicmice. (A)Smallweight-losseffectinUCH-L1
2/2
and UCH-L1
2/2/Thy1-maSN mice as compared to the other genotypes and wildtype mice. (B) Significant reduction in forelimb grip strength in UCH-
L1
2/2/Thy1-maSN mice as compared to unchanged strengths in the other genotypes. (C) Performance of motor coordination assessed on the rotating
beam at 4 rpm. (D) Performance of motor coordination assessed on the rotating beam at 8 rpm. UCH-L1
2/2/Thy1-maSN mice are more severely
impairedascomparedtoUCH-L1
2/2mice.Motorperformancebytheothergenotypeswasnotimpaired.Ageofthemice:2.5months.Dataareshownas
mean6SEM.Seecolourcodeforthedifferentgenotypes.Nnumbersforeachgenotypeareindicated.*p,0.05,**p,0.01(two-tailed,unequalvariances
Student’s t-test).
www.nature.com/scientificreports
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mentation. It was clear that unlike their single UCH-L1
2/2 and
Thy1-maSN mutant littermates, double mutant mice would never
reach an age of 5–6 months or older, as described for mice lacking
either only UCH-L1
42 or over-expressing mouse aSN
41. For
reference, UCH-L1
1/2/Thy1-maSN double and Thy1-maSN single
mutant mice showed no significant differences in performance or
health state (data not shown). Thus, disease worsening is only
observed under conditions of excess murine aSN and a complete
lack of UCH-L1.
UCH-L1 deficiency promotes early-onset astrogliosis in Thy1-
maSN mice. Next, we determined whether UCH-L1-deficiency
combined with excess wildtype aSN affected histopathological
hallmarks of disease and/or pathological aSN protein levels and
species. Over-expression of murine aSN resulted in increased
perikaryal aSN accumulation in the cell soma as illustrated in
hippocampal neurons (Figure 2). The same phenomenon occurs
also in mice expressing human wildtype or A53T mutant aSN
16
but with one distinction: mice expressing murine wildtype aSN
appear to have less and a more diffuse neuritic aSN staining
as opposed to the overall increased intensity and often focal
accumulation type aSN staining patterns observed in neurites of
mice expressing human aSN forms. Stainings of littermate brains
withdifferentgenotypeswerealwaysdoneinparallelandatthesame
time using identical conditions so it remains to be determined whe-
ther epitope masking or other reasons account for this phenomenon
in Thy1-maSN mice. Control littermates and age-matched UCH-
L1
2/2 mice did not show this transgene-specific pattern of
perikaryal aSN immunolabeling in stratum pyramidale neurons.
Instead, UCH-L1
2/2 mice showed a for wildtype mice typical
strong aSN immunolabeling in stratum radiatum and stratum
oriens and virtually no staining in cell soma (Figure 2). At age 3.5
months, Thy1-maSN single and UCH-L1
2/2/Thy1-maSN double
mutants showed similar patterns of perikaryal murine aSN
accumulation in hippocampal neurons (Figure 2). Therefore, the
lack of UCH-L1 by itself does not provoke a perikaryal accumu-
lation of endogenous murine aSN and in double mutants, it does
not significantly alter the pattern of perikaryal aSN accumulation
seen in hippocampal neurons and other brain areas including the
motor cortex, the striatum and the brainstem (Figure 2).
Themostprominentfindingthatdistinguisheddoublefromsingle
mutant mice at the age of 3.5 months was a substantial increase in
astrogliosis. 4/7 double mutant mice as compared to their single
mutant littermates showed massive astrogliosis, especially in the
cortex and to a lesser extent in the hippocampus and the striatum
(Figure 3). This was verified in immunoblots of anterior brain
extracts detecting increased levels of GFAP in 3/6 UCH-L1
2/2/
Thy1-maSNdoublemutantmice(seeSupplementaryFig.S1online).
The fact that not all double mutants showed these histopathological
changes atage 3.5 monthsis notsurprising because wealsoobserved
significant heterogeneity in (i) the age at which disease-onset is phe-
notypically manifest in individual Thy1-maSN mice, (ii) the age-at-
onsetatwhichastro-andmicrogliosisoccursinthemostprofoundly
affected brain regions such as brainstem in Thy1-maSN mice, and
(iii) the age at which end-stage pathology and disease is reached
(varies between 6 and 10 months). Puzzling is that other brain
regions including e.g. cerebellum, brainstem, and thalamus showed
no signs of astrogliosis (Figure 3 and data not shown). Also, all brain
regions examined in 3.5 month old mice were devoid of enhanced
ubiquitin staining, microgliosis and axon degeneration (data not
shown), whichall are histopathological changes present in end-stage
Thy1-maSN mice
41. In summary, excess aSN in UCH-L1-deficient
mice specifically leads to an early-onset astrogliosis in forebrain
regionswhereneuronsexpresshighlevelsoftransgene-derived aSN.
UCH-L1 deficiency in Thy1-maSN mice does not alter the levels
of monomeric, oligomeric or S129-phosphorylated aSN forms.
Immunoblot analysis of the soluble protein fraction extracted from
forebrainandbrainstem regionsof3.5-month-oldThy1-maSNmice
revealed,besidesincreasedlevelsofmonomericaSN,high-molecular
weightaSNforms aswellastruncated speciesandincreased levels of
S129-phosphorylated aSN (Figure 4A and 4B). We have described
similar soluble aSN species in mice over-expressing the human
aSN(A53T) mutant
43. The lack of UCH-L1 in the double mutant
mice did not significantly change the pattern and level of aSN
species seen in single Thy1-maSN mutants (Figure 4A, 4B and
4C). In addition, UCH-L1
2/2 and wildtype littermates showed
indistinguishable levels and patterns of soluble aSN species
(Figure 4A, 4B and 4C). Finally, genotype-specific differences were
also not observed following immunoblotting the insoluble aSN
(pellet) fractions (data not shown).
Figure 2 | aSNstaininginUCH-L1
2/2/Thy1-maSNdoubleascomparedtoThy1-maSNsingletransgenicmice. Paraffin-embeddedsagittalbrainslices
were stained for aSN. Hippocampus, motor cortex, striatum and brainstem for wildtype (WT), UCH-L1
2/2, Thy1-maSN and UCH-L1
2/2/Thy1-maSN
mice are displayed. Brain regions and genotypes are indicated. Age of the animals: 3.5 months. Scale bars: 100 mm and for higher magnification pictures
50 mm.
www.nature.com/scientificreports
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has been reported
30 and these histopathological changes seem con-
finedtothegracile nucleus inthebrainstem. Weanalyzed cSNlevels
by Western blot in brainstem and forebrain extracts from UCH-
L1
2/2 and double mutant mice but these proved similar (Figure 5)
suggesting that the lack of UCH-L1 did not significantly affect aSN
or cSN levels. For reference, the levels of endogenous huntingtin
protein, which are regulated by proteasomal degradation, were also
unaffected by UCH-L1 ablation (Figure 5).
Discussion
Collectively,ourdatashowthatUCH-L1-deficiencyandexcessmur-
ine wildtype aSN in mice act additively to aggravate disease. The
disease process is accompanied by a massive astrogliosis in brain
areas such as cortex, a phenomenon that is not seen in either of
the single mutant mice. We found no evidence for UCH-L1-
deficiency causing any significant changes in pathological aSN
protein levels or species including S129-phosphorylated aSN and
oligomers. Nor did we detect an earlier onset of immunohistopatho-
logical changes that are typically seen in end-stage aSN mice. It is
therefore tempting to speculate that the observed disease-worsening
effects occur by a mechanism that involves excess aSN exacerbating
UCH-L1 deficiency and not vice versa. A perhaps provocative idea
that will need further experimental support is that excess aSN may
compromise UCH-L1 activity as part of aSN’s pathophysiological
effects in central and peripheral synapses.
UCH-L1 is widely expressed in brain and an abundant neuronal
enzyme associated with several neurodegenerative diseases and can-
cer
17,18.UCH-L1proteinisalsofoundinneuronalinclusionsofhuman
PD and DLB brains
23, which perhaps in part explains the decreases in
UCH-L1 activity that have been observed in such brain tissue
38,39.
UCH-L1 belongs to a family of enzymes that disassembles polyubi-
quitin chains to increase availability of free monomeric ubiquitin
19,44.
Inadditiontoitshydrolaseactivity,UCH-L1hasbeenshowntohavea
dimerization-dependent ubiquityl ligase activity
21. This latter activity
was proposed to be in part pathogenic by causing an accumulation of
aSN-ubiquitin conjugates and inhibiting aSN degradation, perhaps
impairing also ubiquitin-proteasome activity
21. Scenarios independ-
ent of UCH-L1 that impair ubiquitin-proteasome activity have also
been postulated to explain aSN accumulation and the formation of
Lewy inclusions in PD and other a-synucleinopathies
45–47.
In gad mice, loss of UCH-L1 leads to bSN and cSN pathology in
specific brain nuclei and it gives rise to a dramatic phenotype that
includes sensory ataxia, motor paresis and eventually premature
death
29,30,48. aSN pathology, however, has not been detected in gad
and other UCH-L1-deficient mice. The observed increase in bSN in
gad mice has been proposed as one possible explanation why aSN
failstoaccumulateinthesemicebecauseothershaveshownthatbSN
cancounteract aSN aggregation
49.Alternatively, UCH-L1deficiency
itself might suppress aSN aggregation.
Excessive amounts of murine wildtype aSN likely challenge
the ubiquitin-proteasome protein-degradation machinery. UCH-
L1 deficiency may compromise this system even further although
direct evidence is lacking that the catalytic activity ofthe proteasome
per se is significantly reduced when UCH-L1 is decreased
50. On the
other hand, UCH-L1 deficiency does reduce ubiquitin levels in the
nervous system and this is accompanied by an up-regulation of lyso-
somal components. Therefore, Walters and colleagues put forward
the hypothesis that UCH-L1 deficiency might affect a pool of ubi-
quitin that is utilized for lysosomal trafficking
31. It is tempting to
speculate whether excess aSN further compromises a lysosomal
route in UCH-L1 mice because synuclein can not only impair cha-
perone-mediated autophagy but the protein itself seems to undergo
intra-lysosomal degradation involving cathepsin D
51. Further evid-
ence is needed to strengthen or refute such a mechanism. Finally, we
can not fully rule out the possibility that excess aSN and UCH-L1
deficiency act via two entirely independent pathways acting none-
theless additively to worsen disease.
Functional abnormalities in double mutants (earlier-onset motor
deficits and increased muscle weakness) were already obvious at the
age of 2.5 months but did not occur in mice that either over-express
murine aSN in awildtype UCH-L1 background or lack UCH-L1 but
had wildtype aSN levels. At the age of 3.5 months, double mutants
displayed one major histopathological change pointing at specific
Figure 3 | Astrogliosis in 3.5-month-old UCH-L1
2/2/Thy1-maSN mutant mice. Paraffin-embedded sagittal brain slices were stained for GFAP.
Hippocampus, motor cortex, striatum and brainstem for wildtype (WT), UCH-L1
2/2, Thy1-maSN and UCH-L1
2/2/Thy1-maSN mice are displayed.
Brain regions and genotypes are indicated. Scale bars: 100 mm and for higher magnification pictures 50 mm.
www.nature.com/scientificreports
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brainareasincluding cortex,hippocampusandstriatum.Neurons in
these brain areas express high levels of the aSN transgene but none-
theless remain largely devoid of hallmark histopathological cellular
changes such as synuclein and ubiquitin pathology and axonal
degeneration seen in brainstem and spinal neurons of end-stage
Thy1-maSN mice
41. Interestingly, the brainstem in our double
mutants showed no astrogliosis or microgliosis unlike in end-stage
Thy1-maSN mice. Whythe forebrain-selective astrogliosis occurs in
the double mutants is currently unknown. aSN seems to play a key
role in the maintenance of SNARE-complex assembly and vesicle
turnover in presynaptic terminals
52–54and it seems likely that excess-
ive amounts of aSN can perturb synaptic function that might trigger
adaptive changes in astrocytes
55,56. Astrogliosis is for example
detected in mice showing enhanced synaptic excitability because of
an editing-deficient GluR-B (GluA2) glutamate receptor subunit
57.
The combination of excess aSN together with UCH-L1 deficiency,
which by itself is known to cause defects in central and peripheral
synapses, perhaps suffices to pass a synaptic insult threshold that
triggers astrocyte activation. Why this would occur mainly in fore-
brain and not in brain areas that otherwise seems most sensitive to
aSN-induced pathology such as brainstem remains speculative.
UCH-L1 is strongly expressed in both forebrain and brainstem
48,58.
Perhaps forebrain neurons are more responsive to a loss of UCH-L1
whenaSNisinexcess. UCH-L1inhibitionisknowntopreferentially
affect the stability of certain synaptic proteins and their role is per-
haps more relevant to forebrain neurons
50. On the other hand, fore-
brain neurons seem normally quite capable of coping with an excess
of aSN because in Thy1-maSN mice, cortical and hippocampal neu-
rons lack the dramatic histopathological changes seen in brainstem
and spinal cord neurons. Possibly, forebrain neurons can better call
upon compensatory mechanisms that reduce synaptic damage that
at the same time trigger astrogliosis which might serve a neuropro-
tectiverole
59,60.Toconclude,furtherexperimentsareneededtobetter
understandifandwhatkindofmolecularinterplaybetweenaSNand
UCH-L1 underlies the disease-worsening effect seen in double
Figure 4 | Brain soluble aSN forms in UCH-L1
2/2/Thy1-maSN and Thy1-maSN mice. (A) Immunoblot analysis of brainstem extracts (supernatant/
soluble fraction) from wildtype, UCH-L1
2/2, Thy1-maSN and UCH-L1
2/2/Thy1-maSN mice detecting aSN, S129-phosphorylated aSN and UCH-L1.
b-actin was used as loading control. Indicated are the oligomers and truncations in mice over-expressing murine aSN. (B) Immunoblot analysis of
anterior brain extracts (supernatant/soluble fraction) from wildtype, UCH-L1
2/2, Thy1-maSN and UCH-L1
2/2/Thy1-maSN mice detecting aSN and
S129-phosphorylated aSN. b-actin is used for loading control. (C) Bar graph depicting quantification of the immunoblots shown in A. and B. for the
different aSN species. See colour code for the different genotypes. Age ofthe animals: 3.5 months. N numbers for each genotype are indicated. Statsitical
analysis: two-tailed, unequal variances Student’s t-test.
www.nature.com/scientificreports
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in regulating monomeric, oligomeric, truncated and phosphory-
lated aSN levels. In addition, it has been reported that no alterations
of dopaminergic cell loss in the absence of UCH-L1 in a viral a-
synucleinopathy model could be observed
33. We can of course not
exclude that compensatory changes in UCH-L1 deficient mice such
asthereportedupregulationoflysosomalenzymeactivitiesincluding
cathepsin D
31, mask a role for UCH-L1 in the clearance of aSN.
Future experiments using conditional UCH-L1 knockouts and/or
determining whether perhaps more subtle effects can be detected
in Thy1-maSN mice treated with UCH-L1 inhibitors or lacking only
one UCH-L1 allele seem worth pursuing.
Methods
Statement on Animal Health. All experiments were carried out in accordance with
authorization guidelines of the Swiss Federal and Cantonal veterinary offices for care
and use of laboratory animals. Studies described in this report were approved by the
Swiss Cantonal veterinary office and performed according toNovartis animallicence
number 2063.
Transgenic mice. Thy1-maSN mice were generated and genotyped as described
41.
aSNknockoutmicewereobtainedfromJacksonlaboratory(JolaHSD)andwerekept
asahomozygousline.UCH-L1knockout(completename:T1320UCHL1)micewere
obtained form Deltagen (San Mateo, CA). Genotyping was performed with
standard PCR protocol with the following primers: Oligo 56474
(59-CTCTCCCCAGACTTAAGCTGCTTTG-39) and Oligo 3196
(59-GGGTGGGATTAGATAAATGCCTGCTCT-39), expected band size of the
targetedallele:496 bp.Oligo67696(59-CCTTGCCTCCGTCCTCTATTAAAGC-39)
andOligo56474,expectedbandsizeoftheendogenous allele:219 bp.Allanimalsare
kept in the C57BL/6 background and littermates were used as controls.
Immunoblot analysis. For infrared Licor western blot analysis brains were
homogenized in homogenization buffer (10 v/w; 0.25 M Sucrose, 20 mM Tris
20 mM pH 7.4, 1 mM EDTA, 1 mM EGTA, 0.5 mM PMSF, 5 mg/mL Pepstatin A, 5
mg/mL Leupeptin, 151000 Okadaic acid 100 ng/ml in ethanol, 151000 Calyculin A
100 ng/ml in ethanol, 15100 Pierce phosphatase inhibitor cocktail) with Precellys24
(Bertin Technologies, Rotation speed 5000 rpm, number of cycles: 2330 sec, pause:
10 sec),thenincubatedfor30 minoniceandsubsequentlycentrifugedat13 krpmat
4uC for 20 min. Supernatant was used and protein concentration was determined by
Bradford (Bio-Rad). 10 mg protein wasloaded (LDS Sample Buffer, Sample Reducing
Agent (Invitrogen), heated for 10 min at 95uC) on NUPAGE 4–12% Bis-tris gel
1.0 mm (Invitrogen) and ran at 180 V for 40–50 min with NuPAGE MES SDS
Running Buffer (Invitrogen). Gels were blotted by semi wet transfer (Invitrogen X
Cell II Blot Module) with NuPAGE Transfer Buffer, 20% methanol on invitrolon
PVDF membrane (Invitrogen) at constant 30 V for 1 h. After transfer proteins were
fixed on membrane (1 min in PBS full power in microwave). For Licor Odyssee
detection membrane was blocked for 1 hr at room temperature in Odyssey Blocking
Buffer (Odyssey, 151 diluted with PBS). Primary Antibodies (anti-phosphorylated
a-synuclein, WAKO, 155000; mouse anti-a-synuclein, BD Transduction
Laboratories, 155000; mouse anti b-actin, SIGMA, 1515000; mouse anti-tubulin,
AA13, abcam, 151000; rabbit anti-UCH-L1, #3524, Cell Signaling, 151000; rabbit
anti-GFAP, Sigma, G9269, 15500; mouse anti-Huntingtin, 2B7, 1 mg/ml; rabbit anti-
c-synuclein,#158,151000)inOdyssey BlockingBuffer(0.2%Tween20). Membranes
were washed 4 times for 5 min at room temperature in PBS containing 0.1%
Tween20 and then incubated for 45 min (light protected) with secondary antibodies
(Alexa Fluor 680, F(ab`)2 fragment of goat anti-mouse 2 mg/mL, 155000; IRDye
800CW anti-rabbit IgG, LI-COR, 155000) in Odyssey Blocking Buffer. Membranes
were again washed 4 times for 5 min at roomtemperature in PBS containing 0.1%
Tween20, then washed 2 times for 10 min at room temperature in PBS only and
finally scanned and quantified on the Odyssey LI-COR System.
Immunohistochemistry. PBS-perfused brains were postfixed overnight in 4%
formalin in PBS at 4uC. Then, the brains were dehydrated by different ethanol
treatments using a Tissue-Tek VIP system (GMI Inc). The ethanol treatment series
consisted of70%, 80%,90%, 2394%, 33100% ethanol each for1 h.Brains were then
washed 2 times in xylol for 30 min followed by 2 times in paraffin (30 min, 60 min).
Subsequent, the dehydrated brains were embedded at 55uC in paraffin using a Tissue
Block System TBS 88 (Geneq Inc). Slices were cut on a Microm HM 355 device
(Microm International GmbH) at a thickness of 4–5 mm and mounted on superfrost
glass slides (Microm International GmbH) and air-dried. Slides were kept at room
temperature until use.
Immunohistochemistry was performed as following: Slides were incubated 3310
min in day-1 buffer (0.01 M PBS, 1% BSA, 0.3% Triton X-100) and blocked by
addition of 4% normal goat serum for 20 min. Paraffin-embedded slides were incu-
bated in day-1 buffer with 1% normal goat serum and subsequently incubated
overnight with a mouse monoclonal aSN antibody (15800, 4B12, Abcam) and rabbit
polyclonal anti-IBA1 (152000, Wako), anti-GFAP (152000, Z0334, Dako) and anti-
ubiquitin (15200, Z458, Dako) in a humidity chamber at room temperature. Slides
werethenrinsed3310 mininday-2buffer(day-1bufferdiluted153in0.01 MPBS).
Slides were incubated for 1 h with secondary antibody (Biotin-conjugated goat anti-
mouse IgG (15200, Vectorlabs) and then with ABC reagent (Vectorlabs) for 1 h at
room temperature. Slides were then rinsed in day-2 buffer 2310 min, in 0.01 M PBS
2320 min and were then desalted in 0.01 M Tris (pH 7.8). Slides were air-dried at
room temperature and coversliped with eukitt mounting medium and analysed on a
Nikon microscope.
Forelimbgripstrengthandrotatingbeam.Tomeasureforelimbgripstrength,mice
are allowed to grasp a handle connected to a force-measuring device (San Diego
Instruments, USA) and then pulled back with their tails until they release the handle.
The best out of four consecutive trials is evaluated.
Tomeasuremotorcoordinationmicewereplacedonarotatingbeam.Therotating
beam was build in-house and is connected to a rotarod (Lugo Basile). It consists of a
metal beam (Ø 1 cm, length 122 cm) coated with rubber attached to a rotarod
(gradient angle upwards of 10u) which controls the constant rotating speed (4 rpm
and 8 rpm). The beam is divided into four equal sections which are used for scoring
theperformanceofthemiceontherotatingbeam(scores1–5).Themouseisplacedat
the beginning on the already rotating beam facing upwards. If the mouse reaches the
endofthebeamwithoutfallingdownorbeingheadfirsthangingonthebeamitgetsa
scoreof1,ifitfallsdownorisheadfirsthanginginthelastsection(4
th)itscoresa2,in
Figure 5 | cSN and huntingtin levels in the UCH-L1
2/2/Thy1-maSN mouse brain. (A) Immunoblot analysis of brainstem extracts from wildtype,
UCH-L1
2/2, Thy1-maSN and UCH-L1
2/2/Thy1-maSN mice detecting soluble cSN. (B) Immunoblot analysis of anterior brain extracts from wildtype,
UCH-L1
2/2,Thy1-maSNandUCH-L1
2/2/Thy1-maSNmicedetectingsolublehuntingtin(Htt).b-actinandtubulinwereusedasloadingcontrols.Ageof
the animals: 3.5 months.
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rdsection3,inthe2
ndsection4andinthe1
stsectionascoreof5.Thereisnotime
limitasthemicereadilygoupwardstherotatingbeam.Onesessionconsistoutoftwo
trials of 4 rpm and two trials of 8 rpm (alltrials were included in the measurements),
whereas the sequence is one trial of 4 rpm followed by on trial of 8 rpm in the
morning and in the afternoon.
Maintenance. The animals were housed in a temperature-controlled room that was
maintained on a 12 h light/dark cycle. Food and water were available ad libitum.
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